Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits

被引:9
|
作者
Shoemaker, DR [1 ]
Saunders, NB [1 ]
Brandt, BL [1 ]
Moran, EE [1 ]
LaClair, AD [1 ]
Zollinger, WD [1 ]
机构
[1] Walter Reed Army Inst Res, Dept Bacterial Dis, Silver Spring, MD 20910 USA
关键词
D O I
10.1128/IAI.73.8.5031-5038.2005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have previously shown that intranasal immunization of mice with meningococcal native outer membrane vesicles (NOMV) induces both a good local mucosal antibody response and a good systemic bactericidal antibody response. However, in the intranasal mouse model, some of the NOMV entered the lung and caused an acute granulocytic response. We therefore developed an alternate animal model using the rabbit. This model reduces the probability of lung involvement and more closely mimics intranasal immunization of humans. Rabbits immunized intranasally with doses of 100 mu g of NOMV in 0.5 ml of saline developed serum bactericidal antibody levels comparable to those of rabbits immunized intramuscularly with 25-mu g doses, particularly when the primary intranasal immunization was given daily for 3 days. Intranasal immunization also induced a local mucosal response as evidenced by immunoglobulin A antibody in saliva, nasal washes, and lung lavage fluids. NONW from a capsule-deficient mutant induced higher serum bactericidal antibody responses than NOMV from the encapsulated parent. Meningococcal NOMV could be administered intranasally at 400 mu g with no pyrogenic activity, but as little as 0.03 mu g/kg of body weight administered intravenously or 25 mu g administered intramuscularly induced a pyrogenic response. These data indicate that the rabbit is a useful model for preclinical testing of intranasal meningococcal NOMV vaccines, and this immunization regimen produces a safe and substantial systemic and local mucosal antibody response.
引用
收藏
页码:5031 / 5038
页数:8
相关论文
共 50 条
  • [31] Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254
    Vipond, C
    Suker, J
    Jones, C
    Tang, C
    Feavers, IM
    Wheeler, JX
    PROTEOMICS, 2006, 6 (11) : 3400 - 3413
  • [32] Label-free quantitative mass spectrometry for analysis of protein antigens in a meningococcal group B outer membrane vesicle vaccine
    Dick, Lawrence W., Jr.
    Mehl, John T.
    Loughney, John W.
    Mach, Anna
    Rustandi, Richard R.
    Ha, Sha
    Zhang, Lan
    Przysiecki, Craig T.
    Dieter, Lance
    Hoang, Van M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (06) : 1518 - 1525
  • [33] Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease
    Holst, J
    Feiring, B
    Fuglesang, JE
    Hoiby, EA
    Nokleby, H
    Aaberge, IS
    Rosenqvist, E
    VACCINE, 2003, 21 (7-8) : 734 - 737
  • [34] Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study
    Paynter, Janine
    Goodyear-Smith, Felicity
    Morgan, Jane
    Saxton, Peter
    Black, Steven
    Petousis-Harris, Helen
    VACCINES, 2019, 7 (01):
  • [35] Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study
    Petousis-Harris, Helen
    Paynter, Janine
    Morgan, Jane
    Saxton, Peter
    McArdle, Barbara
    Goodyear-Smith, Felicity
    Black, Steven
    LANCET, 2017, 390 (10102): : 1603 - 1610
  • [36] A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA
    Keiser, Paul B.
    Gibbs, Barnett T.
    Coster, Trinka S.
    Moran, E. Ellen
    Stoddard, Mark B.
    Labrie, Joseph E., III
    Schmiel, Deborah H.
    Pinto, Valerian
    Chen, Ping
    Zollinger, Wendell D.
    VACCINE, 2010, 28 (43) : 6970 - 6976
  • [37] Enhanced antibody responses to a detoxified lipopolysaccharide-group B meningococcal outer membrane protein vaccine are due to synergistic engagement of Toll-like receptors
    Chen, Wilbur H.
    Basu, Subhendu
    Bhattacharjee, Apurba K.
    Cross, Alan S.
    INNATE IMMUNITY, 2010, 16 (05) : 322 - 332
  • [38] Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac
    Findlow, Jamie
    Taylor, Stephen
    Aase, Audun
    Horton, Rachel
    Heyderman, Robert
    Southern, Jo
    Andrews, Nick
    Barchha, Rita
    Harrison, Ewan
    Lowe, Ann
    Boxer, Emma
    Heaton, Charlotte
    Balmer, Paul
    Kaczmarski, Ed
    Oster, Philipp
    Gorringe, Andrew
    Borrow, Ray
    Miller, Elizabeth
    INFECTION AND IMMUNITY, 2006, 74 (08) : 4557 - 4565
  • [39] Effect of aluminium hydroxide and meningococcal serogroup c capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine
    Rosenqvist, E
    Hoiby, EA
    Bjune, G
    Aase, A
    Halstensen, A
    Lehmann, AK
    Holst, J
    Michaelsen, TE
    Nokleby, H
    Froholm, LO
    Closs, O
    MODULATION OF THE IMMUNE RESPONSE TO VACCINE ANTIGENS, 1998, 92 : 323 - 333
  • [40] Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys
    van der Voort, ER
    Schuller, M
    Holst, J
    de Vries, P
    van der Ley, P
    van den Dobbelsteen, G
    Poolman, J
    VACCINE, 2000, 18 (14) : 1334 - 1343